组织病理学成像和临床数据,包括儿科炎症性肠病的缓解状态
Chloe Martin-King1, Ali Nael2,3, Louis Ehwerhemuepha4,5,6
1Research Institute, Children's Health Orange County (CHOC), Orange, CA, USA. chloe.martin.king@choc.org.
Scientific data
|July 11, 2024
概括
这项研究探讨了使用人工智能 (AI) 来预测儿科炎性肠病 (IBD) 患者的缓解. 人工智能可以通过预测治疗结果,减少试错方法来帮助个性化治疗.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 计算病理学计算病理学
- 生物医学数据科学 生物医学数据科学
背景情况:
- 炎症性肠病 (IBD) 发病率在儿童中不断上升,导致严重的发病率.
- 皮质类固醇是一种常见的治疗方法,具有长期的副作用;无类固醇缓解是质量护理的标准.
- 预测儿科IBD治疗结果具有挑战性,通常涉及试错.
研究的目的:
- 开发和评估人工智能 (AI) 模型,用于预测儿科IBD患者的缓解.
- 为了利用组织病理学图像数据和患者记录来预测结果.
- 为临床决策提供信息,并改进儿科IBD的治疗策略.
主要方法:
- 利用了来自18名儿科IBD患者的951个组织截面扫描的数据集.
- 数据包括患者人口统计,诊断,类固醇使用,缓解状态和幻灯片级分类.
- 人工智能模型经过训练,根据组织病理学和临床数据来预测缓解.
主要成果:
- 人工智能在分类组织部分和预测治疗结果方面表现出潜力.
- 该数据集使得对人工智能驱动的儿科IBD缓解预测的研究成为可能.
- 进一步验证和模型开发正在进行中.
结论:
- 人工智能对预测儿科IBD治疗反应具有前景.
- 这一数据集可以促进人工智能工具的开发,以个性化IBD管理.
- 人工智能辅助预测可以指导治疗决策,朝着无类固醇缓解的方向前进.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease II: Crohn's Disease
212
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
212
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Inflammatory Bowel Disease I: Ulcerative Colitis
160
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
160
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128


